submit to the journals

Allergy Journal Articles, Videos And Insights

Allergy: FEATURED Articles

flipper_slider

Featured articles coming soon...

Editor's choice

European Respiratory and Pulmonary Diseases, 2015;1(1):13 DOI: //doi.org/10.17925/ERPD.2015.01.01.13
European Respiratory and Pulmonary Diseases, 2015;1(1):25–6 DOI: //doi.org/10.17925/ERPD.2015.01.01.25

Allergy: Latest Articles

European Respiratory & Pulmonary Diseases, 2016;2(1):
European Respiratory and Pulmonary Diseases, 2015;1(1):25–6 DOI: //doi.org/10.17925/ERPD.2015.01.01.25
European Respiratory and Pulmonary Diseases, 2015;1(1):13 DOI: //doi.org/10.17925/ERPD.2015.01.01.13
European Respiratory & Pulmonary Diseases, 2015;1(1):11

Allergy: FEATURED VIDEOS

Editor's choice

Claus Bachert discusses nasal polyps and current treatment options. Disclosures: Claus Bachert is the PI of the Dupilumab study. FILMED AT THE EUROPEAN RESPIRATORY SOCIETY (ERS) INTERNATIONAL CONGRESS, SEPTEMBER 2016 Are all nasal polyps alike, or do they have different inflammatory patterns? 00:11 – Actually, nasal polyposis is a heterogeneous disease and they are not alike all over the world, but even not within Europe. We did studies all over the world and it’s very clear that the majority of these patients, certainly in Europe, are so-called type 2 eosinophilic inflammatory disease. But in Asia, they are not. So you have type 2 taking 85% of the patients in Europe and about as little as 15% of the polyp patient population in some parts in Asia. Now in our place, the majority is type 2 mediated, it’s 50% comorbid asthma, and 80% of these patients will have recurrence of disease after surgery if you just look long enough such as 12 years. What are the current treatment options for patients with nasal polyps? 01:16 – It all starts with topical glucocorticoid steroids to treat these patients. This can be once daily, twice daily. It can be in form of drops. You can add some short courses of oral glucocorticoid steroids over the time, not more than three times a year, that’s the recommendation. And then if that doesn’t control the disease, you go to surgery. Now, as I said, even surgery is not a solution to many of these patients. So about 23% in a European survey of patients with polyposis needed at least four or more surgeries at the time of the interview, and actually they were not at end of life so, it’s even higher than that. So clearly, the surgery is a step, a module in between. After the surgery, you still need further therapy with topical or oral glucocorticoid steroids. How prevalent is asthma in patients with chronic sinusitis? 02:26 – The prevalence of asthma comorbidity is very dependent on…in which part in the world you are looking at. As I said, in Europe it’s about 50%. It can be as low as 5% in some places in the world. If you select the patients for the most severe eosinophilic type of inflammation, then you will have up to 70% asthma comorbidity. So it’s very much dependent on whom you look at. And about 10% of these patients also have aspirin-exacerbated respiratory disease. How does the mechanism of action of dupilumab affect the pathogenesis of nasal polyps? 03:13 – As I said, the concern for us is the type 2 inflammation, including cytokines which is IL-4, IL-5 and IL-13. Now dupilumab, is a human monoclonal antibody that binds to the IL-4Rα, and this interferes with IL-4 and IL-13 pathways. In other words, you get an effect on the activation of b cells, of t cells, of eosinophils, mast cells and many other cells. The good thing about this combined thing is that you already target two of these cytokines and you haven’t even targeted the eosinophilic pathway by blocking chemokines locally in the nose, for example; and we have shown that recently. So you’re actually working on IL-4, IL-5 and IL-13 in one way.
EAACI Asthma Section Member, Dr Enrico Heffler, discusses unmet needs in allergy research, challenges in stratifying different allergy phenotypes and potential of microRNAs as biomarkers in asthma. Part 1 of 2. View Part 2 here. Speaker disclosures: nothing to disclose. Filmed at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress, Helsinki, Finland, June 2017.

Allergy: Latest Videos

Video List based on Category on Node Page

Latest Videos

EAACI Asthma Section Member, Dr Enrico Heffler, considers the biggest recent breakthroughs in the use of biologic therapies in allergies and what other molecules may hold promise as biomarkers in allergy and asthma. Part 2 of 2. View Part 1 here. Speaker disclosures: nothing to...
EAACI Asthma Section Member, Dr Enrico Heffler, discusses unmet needs in allergy research, challenges in stratifying different allergy phenotypes and potential of microRNAs as biomarkers in asthma. Part 1 of 2. View Part 2 here. Speaker disclosures: nothing to disclose. Filmed at the European...
Claus Bachert discusses nasal polyps and current treatment options. Disclosures: Claus Bachert is the PI of the Dupilumab study. FILMED AT THE EUROPEAN RESPIRATORY SOCIETY (ERS) INTERNATIONAL CONGRESS, SEPTEMBER 2016 Are all nasal polyps alike, or do they have different inflammatory...
Learn how is climate change affecting allergies and asthma.
20 year old girl is having allergic and vasomotor rhinitis with septal deviation.After septoplasty,Laser turbinoplasty and Coblation surgery is being performed under general anesthesia.
We speak to Dr Ralf Hartmann, an allergologist at the Bundeswehr Armed Forces Hospital in Berlin, about recognizing pollen allergies, how to treat symptoms and the effectiveness of alternative treatments.

LATEST TWEETS

Conference Highlights